Sanofi-Aventis will pay Regeneron a minimum of $4.3 million annually for five years for knock-out and transgenic models of gene function for target genes identified by Sanofi-Aventis. Sanofi-Aventis
The purpose of the Phase I/II clinical trial is to evaluate the safety and tolerance of Triolex when administered orally for 28 days at three different dose levels.
Under the terms of the amended license agreement, XTL will receive an additional non-refundable payment of $2 million in return for reduction in future contingent payments. Under the
TGen Drug Development Services (TD2) will provide key drug development and regulatory services related to the clinical development of NeuVax, Apthera’s lead immunotherapy drug indicated for the adjuvant
IGI with Cancer Health Solutions Resources (CHS) will develop a Novasome technology based over the counter sunscreen product containing CHS’s proprietary ingredients that may enhance the antioxidant effect
Mr Krayacich will be responsible for leading the company’s drug and business development for ganaxolone, an adult and pediatric epilepsy candidate in Phase II, and chelerythrine, a preclinical
Gioacchino Chirico, president and CEO of Immucor, said: “We are pleased to have completed this acquisition, which we believe will enable us to provide innovative molecular diagnostic solutions
In exchange for all of the company’s operating assets, Clinical Data paid $11 million in cash, and entered into a $22 million, five-year promissory note and a separate
The last of around 4,500 patients was recruited in the final week of June 2008, and the three-year study will be conducted in North and South America, Europe
Each study, conducted under an FDA special protocol assessment, met all primary endpoints and showed statistically significant results. The pivotal, Phase III placebo-controlled studies investigating the efficacy and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.